YONKERS, N.Y., March 5, 2010 (GLOBE NEWSWIRE) -- Today, Aureon Laboratories, Inc. announced a new name for its post-prostatectomy, prognostic test available for patients who have undergone surgery to treat their prostate cancer. Commercially available since February 2006, Post-Op Px™ (previously known as Prostate Px), was the first diagnostic test to predict prostate cancer recurrence and disease progression post treatment. For over four years, Post-Op Px has integrated tissue, clinical and molecular information to enable physicians and their patients to make more informed decisions about post-surgical, adjuvant therapies. In addition, Aureon’s other commercially available prognostic test, Prostate Px+, was launched in 2008 and uses biopsy tissue to predict disease progression (metastasis, progression through a castrate state) at diagnosis, prior to treatment.
